Back to discover

Protein / target

Tumor necrosis factor receptor superfamily member 11A

Encoded byTNFRSF11AQ9Y6Q6Homo sapiensSwiss-Prot
UniProt: Q9Y6Q6Ensembl: ENSG00000141655HGNC: HGNC:11908NCBI Gene: 8792
Antibody-tractable
Druggability
UniProt loc high conf
2
Research papers

Protein at a glance

Biological role

Transmembrane signaling receptor

Strongest disease association

Osteoporosis

Via encoding gene TNFRSF11A · Genetic evidence · score 0.84

Research activity

Emerging research

2 papers · latest 2001

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis.

View complete UniProt function annotation

Receptor for TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis (PubMed:9878548). Its interaction with EEIG1 promotes osteoclastogenesis via facilitating the transcription of NFATC1 and activation of PLCG2 (By similarity). Involved in the regulation of interactions between T-cells and dendritic cells (By similarity)

Subcellular location

Cell membraneMembrane raft
Domains and Gene Ontology detail (33)

Gene Ontology

  • Cexternal side of plasma membrane
  • Cmembrane raft
  • Cplasma membrane
  • Fcytokine binding
  • Fmetal ion binding
  • Fsignaling receptor activity
  • Ftransmembrane signaling receptor activity
  • Ftumor necrosis factor receptor activity
  • Padaptive immune response
  • Pcell-cell signaling
  • Pcellular response to zinc ion starvation
  • Pcircadian temperature homeostasis

616 aa · 66 kDa · 6 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOCell migrationGOImmune signallingGO
View supporting evidence

Cell proliferation & survival

  • ·positive regulation of cell population proliferation

Cell migration

  • ·monocyte chemotaxis

Immune signalling

  • ·cytokine binding
  • ·adaptive immune response
  • ·response to interleukin-1

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TNFRSF11A

Gene-level evidence surfaced through the gene TNFRSF11Athat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Osteoporosis
0.85Well supported

Genetic evidence dominant · Open Targets 0.53

Hypothyroidism
0.72Moderately supported

Genetic evidence dominant · Open Targets 0.44

Asthma
0.71Moderately supported

Genetic evidence dominant · Open Targets 0.44

Rhinitis, Allergic
0.70Moderately supported

Genetic evidence dominant · Open Targets 0.42

bone Paget's disease
0.68Moderately supported

Genetic literature evidence dominant · Open Targets 0.61

View evidence synthesis (5)
OsteoporosisWell supported
0.85
agreement 0.72–0.99
Genetic89%Literature11%

Open Targets aggregate 0.53 · 2 independent evidence families

HypothyroidismModerately supported
0.72
agreement 0.58–0.85
Genetic100%Literature0%

Open Targets aggregate 0.44 · 2 independent evidence families

AsthmaModerately supported
0.71
agreement 0.57–0.85
Genetic90%Literature10%

Open Targets aggregate 0.44 · 2 independent evidence families

Rhinitis, AllergicModerately supported
0.70
agreement 0.58–0.82
Genetic100%

Open Targets aggregate 0.42 · 1 independent evidence family

bone Paget's diseaseModerately supported
0.68
agreement 0.55–0.80
Genetic literature72%Animal model25%Literature4%Geneticdup

Open Targets aggregate 0.61 · 3 independent evidence families · 1 not counted as duplicate

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
bone Paget's disease0.61
Osteoporosis0.53
Bone Diseases0.44
Asthma0.44
Hypothyroidism0.44
Rhinitis, Allergic0.42

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas loc

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

urticaria and AngioedemaClinPGx

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Research activity

2 papers · to 2001

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.1,589 cites

Suda T · Endocrine reviews · 1999

Minireview: the OPG/RANKL/RANK system.953 cites

Khosla S · Endocrinology · 2001

Recent

Minireview: the OPG/RANKL/RANK system.

Khosla S · Endocrinology · 2001

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Suda T · Endocrine reviews · 1999

Europe PMC papers linked directly to this protein.